VCIM
ACRS icon

Velan Capital Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Velan Capital Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,700
Closed -$62.1K – 47
2025
Q3 		$62.1K Hold
32,700
– – 0.06% 48
2025
Q2 		$46.4K Sell
32,700
-2,300
-7% -$3.11K 0.05% 46
2025
Q1 		$53.5K Buy
35,000
+8,000
+30% +$17.1K 0.06% 38
2024
Q4 		$67K Buy
+27,000
New +$67.2K 0.06% 33
2024
Q1 		– Sell
-1,761,595
Closed -$1.85M – 22
2023
Q4 		$1.85M Buy
+1,761,595
New +$5.37M 1.08% 15

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Velan Capital Investment Management's ACRS Position: Q4 2025 in Review

Velan Capital Investment Management sold out of Aclaris Therapeutics (ACRS) in Q4 2025, closing a stake of 32,700 shares — an estimated $62.1K sold.

Velan Capital Investment Management first reported a position in ACRS in Q4 2023 and held it in 5 quarters. The position peaked at $1.85M in Q4 2023. 122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Velan Capital Investment Management reported no remaining Aclaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Velan Capital Investment Management sold 32,700 Aclaris Therapeutics shares in Q4 2025, an estimated $62.1K.
  • Velan Capital Investment Management first reported a position in Aclaris Therapeutics in Q4 2023 and held it in 5 quarters.
  • Velan Capital Investment Management's Aclaris Therapeutics position peaked at $1.85M in Q4 2023.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Velan Capital Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.